These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36187123)

  • 1. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
    Garcia de Lucas MD; Miramontes-González JP; Avilés-Bueno B; Jiménez-Millán AI; Rivas-Ruiz F; Pérez-Belmonte LM
    Front Endocrinol (Lausanne); 2022; 13():995646. PubMed ID: 36187123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.
    Hansen KB; Svendstrup M; Lund A; Knop FK; Vilsbøll T; Vestergaard H
    Diabet Med; 2021 Oct; 38(10):e14655. PubMed ID: 34291491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
    Vilsbøll T; Lindahl CØ; Nielsen NF; Tikkanen CK
    Diabetes Obes Metab; 2023 Jun; 25(6):1740-1749. PubMed ID: 36809678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
    Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
    BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
    Yale JF; Catarig AM; Grau K; Harris S; Klimek-Abercrombie A; Rabasa-Lhoret R; Reardon L; Woo V; Liutkus J
    Diabetes Obes Metab; 2021 Oct; 23(10):2269-2278. PubMed ID: 34142429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
    Di Dalmazi G; Coluzzi S; Baldassarre MPA; Ghit A; Graziano G; Rossi MC; Ciappini B; Milo M; Carrieri F; Nicolucci A; Consoli A; Formoso G
    Front Endocrinol (Lausanne); 2022; 13():892702. PubMed ID: 35909534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.
    Napoli R; Berra C; Catarig AM; Di Loreto C; Donatiello E; Berentzen TL; Pitocco D; Giorgino F
    Diabetes Obes Metab; 2023 Jun; 25(6):1658-1667. PubMed ID: 36789682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
    Wolffenbuttel BHR; Brugts MP; Catarig AM; Clark A; Kok M; Lieverse AG; van Soest J
    Adv Ther; 2023 Mar; 40(3):920-933. PubMed ID: 36542260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
    Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
    Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study).
    Caballero Mateos I; García de Lucas MD; Doulatram-Gamgaram VK; Moreno-Moreno P; Jimenez-Millan AI; Botana-López M; Merino-Torres JF; Soto-Gónzalez A; Fernández-García JC; Morales-Portillo C
    Nutrients; 2024 Aug; 16(15):. PubMed ID: 39125424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.
    Ruan Z; Jiang Y; Shi H; Jia R; Ung COL; Hu H
    Expert Rev Clin Pharmacol; 2023 Feb; 16(2):161-176. PubMed ID: 36706368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
    Overgaard RV; Lindberg SØ; Thielke D
    Diabetes Obes Metab; 2019 Jan; 21(1):43-51. PubMed ID: 30047216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).
    Brown RE; Bech PG; Aronson R
    Diabetes Obes Metab; 2020 Nov; 22(11):2013-2020. PubMed ID: 32538541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
    Jain AB; Reichert SM; Amadid H; Braae UC; Bradley RM; Kim JW; Soo V; Yale JF
    Diabetes Obes Metab; 2024 May; 26(5):1799-1807. PubMed ID: 38468125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
    Ji L; Dong X; Li Y; Li Y; Lim S; Liu M; Ning Z; Rasmussen S; Skjøth TV; Yuan G; Eliaschewitz FG
    Diabetes Obes Metab; 2021 Feb; 23(2):404-414. PubMed ID: 33074557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.
    Rudofsky G; Catarig AM; Favre L; Grau K; Häfliger S; Thomann R; Schultes B
    Diabetes Res Clin Pract; 2021 Aug; 178():108931. PubMed ID: 34217773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
    Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL;
    Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.